For the year ending 2025-12-31, RGNX made $170,441K in revenue. -$193,824K in net income. Net profit margin of -113.72%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenues | 170,441 | |||
| Cost of license and royalty revenues | 20,298 | |||
| Research and development | 228,299 | |||
| General and administrative | 82,863 | |||
| Other operating expenses | -179 | |||
| Total operating expenses | 331,639 | |||
| Loss from operations | -161,198 | |||
| Interest income from licensing | 83 | |||
| Investment income | 12,245 | |||
| Interest expense | 45,008 | |||
| Total other income (expense) | -32,680 | |||
| Net loss | -193,878 | |||
| Unrealized gain on available-for-sale securities, net | 54 | |||
| Total other comprehensive income | 54 | |||
| Comprehensive loss | -193,824 | |||
| Basic EPS | -3.76 | |||
| Diluted EPS | -3.76 | |||
| Basic Average Shares | 51,573,000 | |||
| Diluted Average Shares | 51,573,000 | |||
REGENXBIO Inc. (RGNX)
REGENXBIO Inc. (RGNX)